Wolverine Asset Management LLC Immatics N.V. Transaction History

Wolverine Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$11.01 - $12.62 $7,971 - $9,136	724 Added 17.58%	4,843 $56,000
Q2 2023 Aug 07, 2023	SELL	$5.92 - $12.72 $16,043 - $34,471	-2,710 Reduced 39.68%	4,119 $47,000
Q4 2022 Feb 01, 2023	SELL	$8.05 - $11.58 $3,236 - $4,655	-402 Reduced 5.56%	6,829 $59,000
Q3 2022 Nov 10, 2022	BUY	$3.31 - $13.06 $7,867 - $31,043	2,377 Added 48.97%	7,231 $72,000
Q2 2022 Aug 03, 2022	BUY	$6.0 - $9.37 $29,124 - $45,481	4,854 New	4,854 $42,000
Q1 2022 May 04, 2022	SELL	$6.64 - $12.85 $7,682 - $14,867	-1,157 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$10.81 - $14.38 $1,448 - $1,926	-134 Reduced 10.38%	1,157 $15,000
Q3 2021 Nov 12, 2021	BUY	$11.58 - $15.46 $13,386 - $17,871	1,156 Added 856.3%	1,291 $16,000
Q2 2021 Aug 13, 2021	BUY	$10.43 - $12.81 $1,408 - $1,729	135 New	135 $1,000
Q4 2020 Feb 12, 2021	SELL	$9.67 - $12.05 $6,769 - $8,435	-700 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$8.73 - $15.15 $6,111 - $10,605	700 New	700 $7,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.